Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense
Despite scant evidence that it works, the drug, Aduhelm, is predicted to generate billions of dollars in revenue, much of it from Medicare.
- Next story Using light to monitor cancer
- Previous story New heart metric may improve survival for heart-failure patients, study finds
Explore more
- Pandemic-driven telehealth proves popular at safety net health system
As state and federal authorities decide whether to continue reimbursing for telehealth... - Global Coronavirus Deaths Pass 3 Million as Variants Surge
Infections around the world total more than 140 million and over 870... - Study sheds light on mysterious genotype-phenotype associations
A new study analyzing the association between an individual’s genetics (genotype) and... - The vaccine passport debate isn’t new. It started in 1897 during a plague pandemic
Vaccine passports have been touted by some as our ticket to normalcy... - India is churning out wealthy tech elites. Now they need to start making money
This time last year, Indian entrepreneurs were in panic mode. - The Qualcomm Snapdragon 778G brings premium features to a cheaper chip
Qualcomm has announced yet another 7-series chip, in the form of the... - The Super League Founders Are Now at War With One Another
Real Madrid, Juventus and Barcelona are threatening to extract damages from their... - MacOS and iPadOS will never merge — and the M1 iPad Pro is proof
Think the new M1 iPad Pro means iOS and MacOS are merging?... - Best early Memorial Day tech deals you can shop today
Get a jump on Memorial Day savings with these tech deals on... - The new Dell XPS 13 laptop is so deeply discounted it’s unbelievable
The Dell XPS 13, a reliable laptop that doesn’t sacrifice form or...